Understanding how cancer treatments affect heart function
Defining Novel Cardiovascular Mechanisms For TKI Induced Excitability
This study is looking at how a common kidney cancer treatment called Tyrosine Kinase Inhibitors (TKIs) might affect heart health, especially in terms of heart rhythm, so we can find ways to help protect the hearts of people who have survived cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10907848 on NIH RePORTER |
What this research studies
This research investigates the effects of Tyrosine Kinase Inhibitors (TKIs), a common treatment for kidney cancer, on heart function and excitability. It focuses on how these medications can lead to heart-related side effects, particularly arrhythmias, by altering the behavior of specific ion channels in heart cells. The study employs advanced techniques to analyze the mechanisms by which TKIs increase reactive oxygen species and affect cardiac signaling pathways. By understanding these processes, the research aims to identify potential strategies for protecting the heart in cancer survivors.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer survivors, particularly those who have been treated with Tyrosine Kinase Inhibitors for kidney cancer.
Not a fit: Patients who have not undergone treatment with TKIs or those without a history of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart health and reduced cardiac complications for cancer survivors undergoing TKI treatment.
How similar studies have performed: Previous research has indicated that understanding the cardiac effects of cancer treatments can lead to significant advancements in patient care, suggesting that this approach has potential for success.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Smith, Sakima Ahmad — Ohio State University
- Study coordinator: Smith, Sakima Ahmad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.